{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:28:45Z","timestamp":1790692125582,"version":"4.1.0"},"reference-count":32,"publisher":"Impact Journals, LLC","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2020,12,8]]},"DOI":"10.18632\/oncotarget.27827","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T16:52:21Z","timestamp":1607446341000},"page":"4570-4581","source":"Crossref","is-referenced-by-count":15,"title":["Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites"],"prefix":"10.18632","volume":"11","author":[{"given":"Judith E.","family":"den Ouden","sequence":"first","affiliation":[{"name":"Radboud Institute for Health Sciences, Radboud University Medical Center, Obstetrics and Gynecology, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido J.R.","family":"Zaman","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Dylus","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoon M.","family":"van Doornmalen","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried R.","family":"Mulder","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Grobben","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmina E.","family":"van Riel","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[{"name":"Radboud Institute for Health Sciences, Radboud University Medical Center, Obstetrics and Gynecology, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier C.","family":"Buijsman","sequence":"additional","affiliation":[{"name":"Netherlands Translational Research Center B.V., Oss, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"van Altena","sequence":"additional","affiliation":[{"name":"Radboud Institute for Health Sciences, Radboud University Medical Center, Obstetrics and Gynecology, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"1","unstructured":"American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society. 2019."},{"key":"2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","article-title":"No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands","volume":"8","author":"Kruitwagen","year":"2018","journal-title":"Eur J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1002\/cncr.32595","article-title":"Biomarkers in ovarian cancer: To be or not to be","volume":"12","author":"Birrer","year":"2019","journal-title":"Cancer"},{"key":"4","unstructured":"Dutch Guideline on Epithelial Ovarian Cancer. Oncoline. 2020. https:\/\/www.oncoline.nl\/ovariumcarcinoom."},{"key":"5","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"35","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12885-015-1101-8","article-title":"Prediction of resistance to chemotherapy in ovarian cancer: a systematic review","volume":"1","author":"Savage","year":"2015","journal-title":"BMC Cancer"},{"key":"7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.Ccr-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"2","author":"Scroggins","year":"2014","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"101909","DOI":"10.1016\/j.ctrv.2019.101909","article-title":"Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status","volume":"8","author":"Panici","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"9","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.Cd-15-0714","article-title":"Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer","volume":"5","author":"D'Andrea","year":"2015","journal-title":"Cancer Discov"},{"key":"10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/humu.23137","article-title":"Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas","volume":"3","author":"Bulten","year":"2017","journal-title":"Hum Mutat"},{"key":"11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4149\/neo_2013_071","article-title":"Clinical significance of ascites in epithelial ovarian cancer","volume":"6","author":"Liu","year":"2013","journal-title":"Neoplasma"},{"key":"12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1006\/gyno.2000.5728","article-title":"Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer","volume":"7","author":"Untch","year":"2000","journal-title":"Gynecol Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1245\/s10434-013-2878-9","article-title":"Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma","volume":"2","author":"McNally","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12885-015-1511-7","article-title":"Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers","volume":"1","author":"Piche","year":"2015","journal-title":"BMC Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2013.07.105","article-title":"Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma","volume":"13","author":"Chen","year":"2013","journal-title":"Gynecol Oncol"},{"key":"16","doi-asserted-by":"publisher","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","article-title":"Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: Molecular phenotype of chemoresistant ovarian tumors","volume":"7","author":"Ahmed","year":"2012","journal-title":"PLoS ONE"},{"key":"17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"1","author":"Kaye","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.Cd-18-0474","article-title":"Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids","volume":"8","author":"Kochupurakkal","year":"2018","journal-title":"Cancer Discov"},{"key":"19","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fonc.2018.00562","article-title":"Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report","volume":"8","author":"van Altena","year":"2018","journal-title":"Front Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"8451728","DOI":"10.1155\/2016\/8451728","article-title":"Bacteria in Cancer Therapy: Renaissance of an Old Concept","volume":"201","author":"Weiss","year":"2016","journal-title":"Int J Microbiol"},{"key":"21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ygyno.2016.05.007","article-title":"Ovarian cancer and the immune system - The role of targeted therapies","volume":"14","author":"Arend","year":"2016","journal-title":"Gynecol Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data","volume":"15","author":"Glasspool","year":"2019","journal-title":"Gynecol Oncol"},{"key":"23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","article-title":"Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance","volume":"15","author":"deFazio","year":"2018","journal-title":"Gynecol Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"4","author":"Dodd","year":"2009","journal-title":"Eur J Cancer"},{"key":"25","first-page":"419","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"2","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"26","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO)","volume":"11","author":"Pfisterer","year":"2009","journal-title":"Cancer"},{"key":"27","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"10","author":"Fujii","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"14","author":"Nelson","year":"2016","journal-title":"Gynecol Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"e2219","DOI":"10.21769\/BioProtoc.2219","article-title":"Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites","volume":"7","author":"de Vries","year":"2017","journal-title":"Bio Protoc"},{"key":"30","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2method","volume":"2","author":"Schmittgen","year":"2001","journal-title":"Methods"},{"key":"31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0197-1859(00)80002-3","article-title":"A journey through flow cytometric immunofluorescence analyses \u2013 Finding accurate and robust algorithms that estimate positive fraction distributions","volume":"1","author":"Bagwell","year":"1996","journal-title":"Clin Immunol Newsl"},{"key":"32","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1535-7163.MCT-16-0403","article-title":"Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K\/mTOR, Aurora kinase and EZH2 inhibitors","volume":"1","author":"Zaman","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T00:36:41Z","timestamp":1612658201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":32,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2020,12,8]]}},"alternative-id":["27827","33346216"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27827","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}